<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00676845</url>
  </required_header>
  <id_info>
    <org_study_id>DSE-866/47</org_study_id>
    <secondary_id>2007-003131-23 EudraCT number</secondary_id>
    <nct_id>NCT00676845</nct_id>
  </id_info>
  <brief_title>Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection</brief_title>
  <acronym>ArtStiff</acronym>
  <official_title>Effect of Olmesartan Medoxomil on Arterial Stiffness and Thickness in Subjects With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Europe, GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will analyse the dose-dependent effect of olmesartan medoxomil on the change in
      arterial stiffness in subjects with hypertension and metabolic syndrome
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from baseline in carotid-femoral pulse wave velocity (PWV)</measure>
    <time_frame>Up to 1 year of double-blind treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in carotid-femoral PWV, after adjustment for change from baseline in mean blood pressure (MBP)as measured at the same visit</measure>
    <time_frame>Up to 1 year of double-blind treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>On blood pressure (BP) lowering, assessed by conventional BP measurement and 24h ambulatory BP measurement (24h-ABPM)</measure>
    <time_frame>Up to 1 year of double-blind treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>On central pulse pressure (PP) and augmentation index (AI)</measure>
    <time_frame>Up to 1 year of double-blind treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>On common carotid stiffness, intima-media thickness (IMT), and internal diameter</measure>
    <time_frame>Up to 1 year of double-blind treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A 3-week placebo run-in period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olmesartan medoxomil oral tablets, at lowest study dosage for 52-week double-blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 4 weeks followed by the highest study dose for 44 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil</intervention_name>
    <description>dosage form: oral tablet; frequency: daily; duration: 52 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>dosage form: tablet; frequency: daily; duration: 3 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil</intervention_name>
    <description>dosage form: oral tablet; frequency: daily; duration: 52 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil</intervention_name>
    <description>dosage form: oral tablet; frequency: daily; duration: 52 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female outpatients

          -  Age greater than or equal to 18 years and less than or equal to 75 years

          -  Hypertension and metabolic syndrome defined, according to the ATP III/IDF 2005 and
             ESH/ESC 2007 definitions, as BP greater than or equal to 130/85 mmHg and &lt;150/95 mmHg
             (i.e. untreated high normal BP or &quot;low range&quot; mild hypertension) and at least 2 of the
             following traits at:

          -  Abdominal obesity (waist circumference &gt;102 cm for men and &gt;88 cm for women)

          -  Triglyceride level greater than or equal to 150 mg/dL

          -  High density lipoprotein (HDL) &lt;40 mg/dL for men and &lt;50 mg/dL for women

          -  Fasting blood glucose greater than or equal to 110 mg/dL and &lt;126 mg/dL (i.e. no type
             2 diabetes)

          -  No anti-hypertensive treatment or treatment with only one anti-hypertensive medication
             within the last 3 months. Note: treatment with angiotensin II receptor blockers
             (ARB)or angiotensin-converting enzyme inhibitors (ACE) is not allowed within the last
             6 months.

        Exclusion Criteria:

          -  Pregnant or lactating female (prerequisite for female subjects of childbearing
             potential: adequate contraception)

          -  Type 1 and type 2 diabetes

          -  &quot;High range&quot; mild hypertension (i.e. systolic blood pressure [SBP]: 150 - &lt;160 mmHg
             and /or diastolic blood pressure [DBP]: 95 - &lt;100 mmHg)

          -  Moderate (SBP: 160 - 179 mmHg and DBP: 100 - 109 mmHg), severe (SBP: greater than or
             equal to 180 mmHg and/or greater than or equal to 110 mmHg), or resistant
             (hypertension resistant to treatment)hypertension

          -  Secondary hypertension of any aetiology, such as renal disease, pheochromocytoma, or
             Cushing's syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nurnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2008</study_first_submitted>
  <study_first_submitted_qc>May 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2008</study_first_posted>
  <last_update_submitted>April 26, 2012</last_update_submitted>
  <last_update_submitted_qc>April 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arterial stiffness</keyword>
  <keyword>Vascular protection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

